Verona Pharma Plc (VRNA)

[PatiencePaysOff79]

$VRNA-Verona Pharma Shares Up 58% Premarket on Positive Topline Results
6:09 AM ET 1/13/20 | Dow Jones


By Chris Wack

Verona Pharma Plc (VRNA) shares rose 58% to $9.42 premarket after the company said it saw positive top-line data from a study evaluating nebulized ensifentrine as an add-on treatment to tiotropium Spiriva Respimat in patients with moderate to severe chronic obstructive pulmonary disease.

The biopharmaceutical said the study met its primary endpoint of improved lung function, with ensifentrine added on to inhaled tiotropium, commonly used to treat COPD.

Ensifentrine produced a clinically and statistically significant, and dose-dependent improvement in peak forced expiratory volume in one second at week 4 compared to placebo added on to tiotropium.

Verona said the primary endpoint was met at all doses, and ensifentrine was well tolerated at all doses with an adverse event profile similar to placebo.

Write to Chris Wack at [e-mail]